Merit Medical Systems has purchased US-based View Point Medical through a merger transaction, making the latter a wholly owned subsidiary.
With this acquisition, Merit has expanded its therapeutic oncology portfolio.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The total transaction value is approximately $140m, including assumed liabilities, with $90m paid in cash at closing.
The remaining consideration will be paid in two deferred instalments of $25m, due no later than the first and second anniversaries of the closing date.
View Point manufactures the OneMark detection imaging system and OneMark tissue markers.
Cleared by the US Food and Drug Administration, the OneMark system includes a surgical detection console and ultrasound-enhanced tissue markers.
The markers are intended to stay detectable across standard imaging methods after placement and are designed to limit disruption during imaging studies. Used alongside Merit’s SCOUT platform, the system could reduce the need for an additional procedure to mark the tumour location before surgery.
From 1 April 2026 to 31 December 2026, Merit expects the acquisition to contribute $2m to $4m in revenue and reduce previously forecast non-GAAP earnings per share by $0.05.
For the 12 months ending 31 December 2027, the deal is expected to contribute revenue of $14m to $16m and is expected to become accretive to non-GAAP earnings per share.
Merit Medical Systems president and CEO Martha Aronson said: “This acquisition expands Merit’s portfolio of therapeutic oncology products dedicated to the accurate diagnosis and localisation of breast and soft tissue tumours.
“View Point’s unique ultrasound-enhanced technology offers a highly innovative solution to localise more lesions at the time of biopsy – representing an estimated 1.3 million procedures annually in the US alone.”
Piper Sandler advised Merit on the financial aspects of the transaction while Baker & McKenzie provided legal counsel.
In August 2025, Merit enrolled the first subject in the multi-centre, prospective trial, WRAP North America registry, aimed at collecting data on the effectiveness and safety of the Wrapsody cell-impermeable endoprosthesis (CIE) device in a real-world clinical setting.
